‘Creating An Environment Where Women Can Thrive’ – Accord’s Carter Discusses The BGMA Women’s Networking Group

Chair Discusses Goals Of Group On International Women’s Day

Marking International Women’s Day, Generics Bulletin speaks to Accord’s UK country manager Clara Carter about her role as chair of the BGMA’s new Women’s Networking Group.

Clara Carter chairs the BGMA Women’s Networking Group (BGMA)

Last November, Clara Carter – UK country manager for Accord Healthcare – was named by the British Generic Manufacturers Association as the first chair of the organization’s new Women’s Networking Group.

With a stated goal of “identifying and nurturing talent and breeding confidence in future industry leaders,” the aim of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Interviews

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By 

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By 

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By 

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By 

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

More from Business

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By 

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By 

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Three’s A Crowd? Celltrion Launches Denosumab In US

 
• By 

A third pair of Prolia and Xgeva rivals has now been launched in the US, with Celltrion throwing its hat into the ring after denosumab launches by Sandoz and Fresenius Kabi. But this is only the beginning for what is shaping up to be another highly competitive biosimilars market.